![](https://go.instem.com/l/864232/2024-03-13/q2g29h/864232/1710348655lezwKabm/ich_s1b_hero.png)
on-demand webcast
Future Proofing Drug Safety: Target Carcinogenicity Risk Assessment Meets ICH S1B(R1) Standards
Let's re-imagine the carcinogenicity assessment
In the fast-paced and cost-conscious 'drug to market' race, momentum can be gained by implementing a Weight of Evidence (WoE) to negate unnecessary preclinical testing. We will present results from a collaboration to standardize a procedural framework supporting the ICH S1B(R1) integrated assessment. Specifically, target biology (WoE #1) will be presented.
This is the concise version of the presentation that was originally shared at the 2024 Annual SOT Meeting and ToxExpo.
![](https://go.instem.com/l/864232/2022-03-16/njlhqr/864232/1647450188c549msVl/Frances_Headshot.jpg)
Frances Hall PhD
Scientific Application Director for In Silico & Translational Science Solutions